Kintara Therapeutics announced the initiation of a REM-001 15-patient clinical trial in cutaneous metastatic breast cancer patients. This open label 15-patient study in CMBC patients is evaluating REM-001, a second-generation photodynamic therapy photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate of the target treatment fields at any time from treatment up to, and including, week 24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>